期刊文献+

Circulating Tumor Cells in Metastatic Breast Cancer:Monitoring Response to Chemotherapy and Predicting Progression-Free Survival 被引量:3

Circulating Tumor Cells in Metastatic Breast Cancer:Monitoring Response to Chemotherapy and Predicting Progression-Free Survival
下载PDF
导出
摘要 Objective:The purpose of this study is to explore RT-PCR method to set up the examination platform for detecting circulating tumor cells(CTC) in peripheral blood from metastatic breast cancer patients.The primary endpoint is to find out the correlation of existence of CTC with clinical responses and progression-free survival(PFS).Methods:The breast cancer cell line MCF-7 was serially diluted into the peripheral blood from 45 healthy donors to set up the sensitivity of RT-PCR assay.The expression of CK19 mRNA was amplified from both 49 patients and 45 healthy donors respectively.The CK19 protein quantity from plasma was measured by competitive inhibition ELISA assay.Results:The sensitivity of RT-PCR could reach 1/106?107 white blood cells with specificity of 95.6%.The objective response rate(ORR) of patients with CK19 mRNA-negative undertaken one cycle chemotherapy was significantly higher than those with positive(P0.0001).PFS among CK19 mRNA-negative patients was also increased,although there was no significance(P=0.098).The results of ELISA assay showed that CK19 protein was decreased significantly after one cycle chemotherapy,which gave rise to a little higher ORR(P=0.015) and increased PFS(P=0.016).Conclusion:Patients with unamplified CK19 mRNA after one cycle chemotherapy could achieve better radiographic evaluation and increased PFS,which was showed to be of consistency with the CK19 protein assay among the patients treated. Objective:The purpose of this study is to explore RT-PCR method to set up the examination platform for detecting circulating tumor cells(CTC) in peripheral blood from metastatic breast cancer patients.The primary endpoint is to find out the correlation of existence of CTC with clinical responses and progression-free survival(PFS).Methods:The breast cancer cell line MCF-7 was serially diluted into the peripheral blood from 45 healthy donors to set up the sensitivity of RT-PCR assay.The expression of CK19 mRNA was amplified from both 49 patients and 45 healthy donors respectively.The CK19 protein quantity from plasma was measured by competitive inhibition ELISA assay.Results:The sensitivity of RT-PCR could reach 1/106?107 white blood cells with specificity of 95.6%.The objective response rate(ORR) of patients with CK19 mRNA-negative undertaken one cycle chemotherapy was significantly higher than those with positive(P0.0001).PFS among CK19 mRNA-negative patients was also increased,although there was no significance(P=0.098).The results of ELISA assay showed that CK19 protein was decreased significantly after one cycle chemotherapy,which gave rise to a little higher ORR(P=0.015) and increased PFS(P=0.016).Conclusion:Patients with unamplified CK19 mRNA after one cycle chemotherapy could achieve better radiographic evaluation and increased PFS,which was showed to be of consistency with the CK19 protein assay among the patients treated.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2010年第3期201-210,共10页 中国癌症研究(英文版)
基金 supported by a grant from the Beijing Capital Development Foundation for Medical Sciences(No.2007-2053)
关键词 Breast cancer Circulating tumor cells CK19 RT-PCR ELISA Breast cancer Circulating tumor cells CK19 RT-PCR ELISA
  • 相关文献

参考文献30

  • 1Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer[J]. J Clin Oncol 2005; 23:1420-30.
  • 2Bauernhofer T, Zenahlik S, Hofmann G, et al. Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer[J]. Oncol Rep 2005; 13: 179-84.
  • 3Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival[J]. Clin Cancer Res 2006; 12:4218-24.
  • 4Kopfstein L, Christofori G. Metastasis: cell- autonomous mechanisms versus contributions by the tumor microenvironment[J]. Cell Mol Life Sci 2006; 63:449-68.
  • 5Swenerton KD, Legha SS, Smith T, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy[J]. Cancer Res 1979; 39:1552-62.
  • 6Yagata H, Nakamura S, Toi M, et al. Evaluation of circulating tumor cells in patients with breast cancer: multi- institutional clinical trial in Japan[J]. Int J Clin Oncol 2008; 13:252-6.
  • 7Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer[J]. Semin Oncol 2006; 33:S9-14.
  • 8Andreopoulou E, Cristofanilli M. Circulating tumor cells as prognostic marker in metastatic breast cancer[J]. Expert Rev Anticancer Ther 2010; 10:171-7.
  • 9Pierga JY, Bidard FC, Denis MG, et al. Prognostic value of peripheral blood double detection of CK19 and MUC1 mRNA positive cells detected by RT-quantitative PCR in 94 breast cancer patients with a follow up of 9 years[J]. Mol Oncol 2007; 1:267-8.
  • 10You F, Roberts LA, Kang SP, et al. Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells[J]. J Hematol Oncol 2008; 1:2.

同被引文献19

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部